- Home
- LGHL vs TNFA Comparison
LGHL vs TNFA Comparison
Compare LGHL & TNFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGHL
- TNFA
- Stock Information
- Founded
- LGHL 2015
- TNFA 2014
- Country
- LGHL Singapore
- TNFA United States
- Employees
- LGHL N/A
- TNFA N/A
- Industry
- LGHL Investment Bankers/Brokers/Service
- TNFA
- Sector
- LGHL Finance
- TNFA
- Exchange
- LGHL Nasdaq
- TNFA NYSE
- Market Cap
- LGHL 1.5M
- TNFA 1.6M
- IPO Year
- LGHL N/A
- TNFA N/A
- Fundamental
- Price
- LGHL $3.92
- TNFA $0.10
- Analyst Decision
- LGHL
- TNFA
- Analyst Count
- LGHL 0
- TNFA 0
- Target Price
- LGHL N/A
- TNFA N/A
- AVG Volume (30 Days)
- LGHL 2.3M
- TNFA 4.6M
- Earning Date
- LGHL 07-22-2025
- TNFA 08-18-2025
- Dividend Yield
- LGHL N/A
- TNFA N/A
- EPS Growth
- LGHL N/A
- TNFA N/A
- EPS
- LGHL N/A
- TNFA N/A
- Revenue
- LGHL N/A
- TNFA N/A
- Revenue This Year
- LGHL N/A
- TNFA N/A
- Revenue Next Year
- LGHL N/A
- TNFA N/A
- P/E Ratio
- LGHL N/A
- TNFA N/A
- Revenue Growth
- LGHL N/A
- TNFA N/A
- 52 Week Low
- LGHL $2.13
- TNFA $0.10
- 52 Week High
- LGHL $21.15
- TNFA $2.16
- Technical
- Relative Strength Index (RSI)
- LGHL 64.34
- TNFA 30.72
- Support Level
- LGHL $2.81
- TNFA $0.11
- Resistance Level
- LGHL $3.27
- TNFA $0.14
- Average True Range (ATR)
- LGHL 0.45
- TNFA 0.02
- MACD
- LGHL 0.11
- TNFA 0.00
- Stochastic Oscillator
- LGHL 83.36
- TNFA 3.64
About LGHL Lion Group Holding Ltd.
Lion Group Holding Ltd is an investor-focused trading platform that offers various products and services. The company's current business lines include total return swap (TRS) trading business, contracts for difference (CFD) trading services, Hong Kong-based Over-The-Counter (OTC) stock options trading business, and futures and securities brokerage services. It provides these services through its Lion Brokers Pro and a variety of other applications. The company generates a majority of its revenue from its CFD trading services business. Geographically, the firm's key revenue-generating market is Hong Kong.
About TNFA TNF PHARMACEUTICALS INC EFFEC
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms, Isomyosamine and Supera-CBD. Isomyosamine is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B. The company has one reportable segment focused on Isomyosamine.